Advances in novel systemic therapies for advanced hepatocellular carcinoma

被引：1

作者：

Carloni, Riccardo ^{[1
]}

Rizzo, Alessandro ^{[2
]}

Cusmai, Antonio ^{[2
]}

Palloni, Andrea ^{[1
]}

Di Federico, Alessandro ^{[1
]}

Di Marco, Mariacristina ^{[1
]}

Massafra, Raffaella ^{[3
]}

Fanizzi, Annarita ^{[3
]}

Palmiotti, Gennaro ^{[2
]}

Brandi, Giovanni ^{[1
]}

机构：

[1] IRCCS Azienda Osped Univ Bologna, Med Oncol, Via Albertoni 15, Bologna, Italy

[2] IRCCS Ist Tumori Giovanni Paolo II, Struttura Semplice Dipartimentale Oncol Med Presa, Viale Orazio Flacco 65, I-70124 Bari, Italy

[3] IRCCS Ist Tumori Giovanni Paolo II, Struttura Semplice Dipartimentale Fis Sanit, Viale Orazio Flacco 65, I-70124 Bari, Italy

来源：

FUTURE MEDICINAL CHEMISTRY | 2022年 / 14卷 / 20期

关键词：

atezolizumab; bevacizumab; hepatocellular carcinoma; immune checkpoint inhibitor; multikinase inhibitor; relatlimab; tislelizumab; VEGF; 1ST-LINE TREATMENT; PHASE-III; DOUBLE-BLIND; OPEN-LABEL; T-CELLS; C-MET; SORAFENIB; GROWTH; COMBINATION; PEMBROLIZUMAB;

D O I：

10.4155/fmc-2022-0045

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Hepatocellular carcinoma (HCC) represents the most frequent type of primary liver tumor. Most HCC patients present with advanced disease at diagnosis and the recurrence rate after surgery remains high. Treatment options for advanced HCC are limited, with sorafenib representing the only systemic agent approved for treatment of advanced HCC in more than a decade. However, in recent years new molecular targeted therapies and immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced HCC. In particular, combinations of ICIs with antiangiogenic drugs, or with other ICIs, represent one of the most promising strategies. Herein we provide a comprehensive overview of the main therapeutic advances in the systemic treatment of HCC, focusing on the most relevant ongoing clinical trials.

引用

页码：1455 / 1470

页数：16

共 134 条

[1] Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View [J].

Abdelrahim, Maen ;

Esmail, Abdullah ;

Saharia, Ashish ;

Abudayyeh, Ala ;

Abdel-Wahab, Noha ;

Diab, Adi ;

Murakami, Naoka ;

Kaseb, Ahmed O. ;

Chang, Jenny C. ;

Gaber, Ahmed Osama ;

Ghobrial, Rafik Mark .

CANCERS, 2022, 14 (07)

[2] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].

Abou-Alfa, G. K. ;

Meyer, T. ;

Cheng, A. -L. ;

El-Khoueiry, A. B. ;

Rimassa, L. ;

Ryoo, B. -Y. ;

Cicin, I. ;

Merle, P. ;

Chen, Y. H. ;

Park, J. -W. ;

Blanc, J. -F. ;

Bolondi, L. ;

Klumpen, H. -J. ;

Chan, S. L. ;

Zagonel, V. ;

Pressiani, T. ;

Ryu, M. -H. ;

Venook, A. P. ;

Hessel, C. ;

Borgman-Hagey, A. E. ;

Schwab, G. ;

Kelley, R. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63

[3] Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA [J].

Abou-Alfa, Ghassan K. ;

Chan, Stephen Lam ;

Kudo, Masatoshi ;

Lau, George ;

Kelley, Robin Kate ;

Furuse, Junji ;

Sukeepaisarnjaroen, Wattana ;

Kang, Yoon-Koo ;

Dao, Tu V. ;

De Toni, Enrico N. ;

Rimassa, Lorenza ;

Breder, Valeriy Vladimirovich ;

Vasilyev, Alexander ;

Heurgue, Alexandra ;

Tam, Vincent ;

Mody, Kabir ;

Thungappa, Satheesh Chiradoni ;

He, Philip ;

Negro, Alejandra ;

Sangro, Bruno .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)

[4]

AKCE M, 2022, THER ADV GASTROENTER, V15, P86126

[5]

[Anonymous], 2019, FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma

[6] Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy. [J].

Ascierto, Paolo Antonio ;

Melero, Ignacio ;

Bhatia, Shailender ;

Bono, Petri ;

Sanborn, Rachel E. ;

Lipson, Evan J. ;

Callahan, Margaret K. ;

Gajewski, Thomas ;

Gomez-Roca, Carlos A. ;

Hodi, F. Stephen ;

Curigliano, Giuseppe ;

Nyakas, Marta ;

Preusser, Matthias ;

Koguchi, Yoshinobu ;

Maurer, Matthew ;

Clynes, Raphael ;

Mitra, Priyam ;

Suryawanshi, Satyendra ;

Munoz-Couselo, Eva .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[7]

AstraZeneca, RAND OP LAB MULT CTR

[8]

AVEO Pharmaceuticals Inc., PHAS 1B 2 OP LAB STU

[9] A narrative review of systemic treatment options for hepatocellular carcinoma: state of the art review [J].

Awosika, Joy ;

Sohal, Davendra .

JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (01) :426-437

[10] Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s). [J].

Bang, Yung-Jue ;

Golan, Talia ;

Lin, Chia-Chi ;

Dahan, Laetitia ;

Fu, Siqing ;

Moreno, Victor ;

Geva, Ravit ;

Reck, Martin ;

Wasserstrom, Heather Ann ;

Mi, Gu ;

Laing, Naomi ;

Goff, Laura Williams .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 6 7 8 9 10 →